PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot… - Molecular cancer, 2023 - Springer
Abstract The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal
transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell …

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

J LoPiccolo, GM Blumenthal, WB Bernstein… - Drug Resistance …, 2008 - Elsevier
The PI3K/Akt/mTOR pathway is a prototypic survival pathway that is constitutively activated
in many types of cancer. Mechanisms for pathway activation include loss of tumor …

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer

HJ Lim, P Crowe, JL Yang - Journal of cancer research and clinical …, 2015 - Springer
Purpose PTEN is an essential tumour suppressor gene which encodes a phosphatase
protein that antagonises the PI3K/Akt/mTOR antiapoptotic pathway. Impairment of this …

PI3K/Akt/mTOR pathway and its role in cancer therapeutics: are we making headway?

Y Peng, Y Wang, C Zhou, W Mei, C Zeng - Frontiers in oncology, 2022 - frontiersin.org
Cancer is a severe public health issue that is a leading cause of mortality globally. It is also
an impediment to improving life expectancy worldwide. Furthermore, the global burden of …

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

L Yu, J Wei, P Liu - Seminars in cancer biology, 2022 - Elsevier
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …

Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells

G Cassinelli, V Zuco, L Gatti, C Lanzi… - Current medicinal …, 2013 - ingentaconnect.com
The deregulation of oncogenic signaling pathways which provide survival advantages to
tumor cells is mediated by multiple cellular networks. Among them, the PI3K-Akt-mTOR axis …

Akt as a therapeutic target in cancer

LS Steelman, KM Stadelman… - Expert opinion on …, 2008 - Taylor & Francis
Background: The phosphatidylinositol 3-kinase (PI3K)/phosphatase and tensin homolog
(PTEN)/v-akt murine thymoma viral oncogene homolog (Akt)/mammalian target of rapamycin …

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway

CA Granville, RM Memmott, JJ Gills, PA Dennis - Clinical Cancer Research, 2006 - AACR
Abstract The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)
pathway controls many cellular processes that are important for the formation and …

[HTML][HTML] The phosphoinositide 3-kinase pathway and therapy resistance in cancer

KK Brown, A Toker - F1000prime reports, 2015 - ncbi.nlm.nih.gov
Abstract The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR)
signaling network is a master regulator of processes that contribute to tumorigenesis and …

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients

SE Ghayad, PA Cohen - Recent patents on anti-cancer drug …, 2010 - ingentaconnect.com
Aberrant activation of the PI3K/Akt/mTOR pathway is found in many types of cancer and thus
plays a major role in breast cancer cell proliferation and anti-cancer drug resistance. The …